GU Cancers Symposium - ASCO ASTRO SUO - 2008 - High-Risk Disease after Radical Retropubic Prostatectomy: The Case for Adjuvant External Beam Radiation Therapy
Saturday, 16 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Anthony Zeitman presented the argument for adjuvant radiotherapy (XRT) following radical prostatectomy (RP).
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - High-Risk Disease after Radical Retropubic Prostatectomy : The Case for Systemic Treatment
Saturday, 16 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Kibel stated that it is systemic disease that kills the patient.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Impact of the Specific Endothelin A Receptor Antagonist ZD4054 on Overall Survival and Bone Metastasis in Patients with Hormone-Resistant Prostate Cancer: Results of a Phase II Trial
Saturday, 16 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Dawson discussed ZD4054, an endothelin A receptor antagonist. Endothelin A promotes angiogenesis, osteoblast stimulation and disease progression.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Novel Therapeutics: What’s on the Horizon?
Saturday, 16 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Carducci discussed what is on the horizon for 2009.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Management of Post-Docetaxel Treatment
Saturday, 16 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Beer reviewed the TAX 327 trial showing a 2 month survival benefit for docetaxel compared to mitoxantrone in patients with metastatic CRPC. A second PSA decline (in 46%) occurs with re-treatment with docetaxel and the effect persists for 5 months or longer in about 45% of these patients.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Androgen Receptor Reactivation after Androgen Deprivation Therapy - Highlight
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Balk discussed the modest clinical benefit of AR antagonists in addition to androgen-deprivation therapy (ADT). However, AR is expressed at levels that are comparable to primary CaP, although the expression may not be heterogeneous.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Metabolic Syndrome in America: Implications for Treatment - Highlight
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Freedland discussed the metabolic syndrome that is a combination of medical disorders that increases one’s risk for cardiovascular (CV) disease.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Potential Targets in Patients with Androgen-Independent Disease
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Gelmann presented the progression of molecular alterations that accompany the clinical progression of CaP.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Prostate Stem Cell Insight into Tumor Initiation
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - John Isaacs, Johns Hopkins discussed stem cell biology.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Prostate-specific Antigen Screening Among Elderly Men with Limited Life Expectancies
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - The US population is living longer, and by 2025 there will be more than one million Americans older than age 100.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - RTOG Genitourinary Radiation Oncology Specialists Reach Consensus on Pelvic Lymph Node Volumes for High-Risk Prostate Cancer
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Lawton discussed the role for pelvic LN XRT in CaP.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Disease Trajectory of Untreated Localized Prostate Cancer in Elderly Men: A Population-Based Study
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Overtreatment of CaP affects QOL for patients.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Cardiovascular Events Among Newly Diagnosed Prostate Cancer Patients
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Emotional stress is associated with CV morbidity and mortality, such as reported during earthquakes, loss of a child and during world cup soccer matches.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Brachytherapy: More is Better
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - A survey in 2002 reported that half of urologists in the US offer brachytherapy.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Correlating Androgen Levels and Steroidogenic Enzyme Expression in Castration-Resistant Prostate Cancer (CRPC) Metastases
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Mostaghel reviewed the potential sources of tissue androgens from the androgen metabolic pathway.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - The Role of MicroRNA in Prostate Tumor Biology
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Nelson discussed that androgen-independent CaP progression is not really independent of androgens.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Cardiovascular Mortality Following Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: Analysis of ROG 85-31
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Androgen-deprivation therapy (ADT) decreases PCSM, but may be associated with greater risk of incident coronary artery disease (CAD), myocardial infarction and diabetes. Data from RTOG 85-31, a large trial of radiotherapy with or without ADT was used for this analysis.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Preliminary Phase II Results of Abiraterone Acetate in Patients with Castration-resistant metastatic Prostate Cancer after Failure of Docetaxel-based Chemotherapy
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Danila, spoke about abiraterone acetate (AA), an oral and irreversible inhibitor of CYP17 that decreases testosterone and DHT levels to undetectable. The study presented sought to determine the proportion of patients achieving a PSA decline of >50% and to assess toxicity.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Androgen Suppression and Radiation Versus Radiation for Prostate Cancer: A Randomized Trial and Analysis of the Prognostic Significance of Comorbidity
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - This study sought to compare survival in a prospective randomized trial of radiotherapy (XRT) alone vs. XRT with 6 months of ADT. 206 men were accrued and randomized. They all had at least one unfavorable-risk factor.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Secondary Androgen Deprivation: Treating the Prostate Specific Antigen or the Patient
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Oh reviewed the past and present of secondary hormonal therapies.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Nutrition and Prostate Cancer
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - June Chan from UCSF presented on Nutritional Epidemiology of Prostate Cancer. In a population migration study, low-risk CaP populations moving to a high-risk area shifted to a higher risk profile.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Side Effects of Local Therapy in the Elderly Male
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Sanda reported on the PROSTQA, which assesses the QOL outcomes for patients treated with RP, XRT and brachytherapy.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Radiation Therapy: How Much Androgen Deprivation Therapy is Enough?
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Sandler reported on a secondary analysis of RTOG 85-31, in which the patients who got longer duration of ADT had better survival.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Effect of Abberant ERG Expression on Prostate Tumorigenesis
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - ETS transcription factors ERG and TMPRSS2 can activate or repress the expression of genes involved in various biological processes. ETS family members in cancer can result in a fusion protein that impacts cancer.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Early Versus Delayed Endocrine Treatment of pN1-3M0 Prostate Cancer without Local Treatment of the Primary Tumor: Results of EORTC Protocol 30846 after 13 Years of Follow-Up – A Phase III Study
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Schroeder discussed early vs. delayed ADT in EORTC 30846.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Death from Prostate Cancer in a Screened Population: Relation to PSA Levels at First Screen in the ERSPC Section Rotterdam
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Within the ERSPC, men with a PSA
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Prostate Cancer-Specific Mortality after Radical Prostatectomy in the Prostate-Specific Antigen Era
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - The long-term risk of CaP specific mortality after RP is poorly defined.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Use of DNA Methylation to Predict the Absence of Prostate Cancer in Men with High Risk and Initially Negative Prostate Biopsy
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Trock addressed the fact that 30% of patients with a negative initial prostate biopsy will be found to have CaP on repeat biopsy.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Surgical Prospectives in High-Risk Prostate Cancer
Friday, 15 February 2008
SAN FRANCISCO, CA (UroToday.com) - Dr. Benson from Columbia University discussed radical prostatectomy (RP) in the treatment of high-risk CaP. Risk assessment is critical and he uses RP as a lumpectomy with adjuvant therapy based upon pathology.
Login to read more...
|
GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Are We Under-Treating the Elderly Male?
Friday, 15 February 2008
San Francisco, CA (UroToday.com) - Dr. Armstrong, a primary care internist and epidemiologist at the University of Pennsylvania presented on prostate cancer in the elderly population.
Login to read more...
|
Conference Coverage 
